{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:14:12Z","timestamp":1759058052657},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T00:00:00Z","timestamp":1587340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s13760-020-01356-9","type":"journal-article","created":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T16:04:18Z","timestamp":1587398658000},"page":"927-931","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Spectrum of anti-myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases: an Indian perspective"],"prefix":"10.1007","volume":"121","author":[{"given":"Jasodhara","family":"Chaudhuri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamoghna","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supratim","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alak","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atanu","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,20]]},"reference":[{"issue":"4","key":"1356_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","volume":"15","author":"S Ramanathan","year":"2016","unstructured":"Ramanathan S, Dale RC, Brilot F (2016) Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 15(4):307\u2013324. https:\/\/doi.org\/10.1016\/j.autrev.2015.12.004","journal-title":"Autoimmun Rev"},{"issue":"9","key":"1356_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/dmcn.13703","volume":"60","author":"S Duignan","year":"2018","unstructured":"Duignan S, Wright S, Rossor T, Cazabon J, Gilmour K, Ciccarelli O et al (2018) Myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies are highly specific in children with acquired demyelinating syndromes. Dev Med Child Neurol 60(9):958\u2013962. https:\/\/doi.org\/10.1111\/dmcn.13703","journal-title":"Dev Med Child Neurol"},{"key":"1356_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3389\/fneur.2018.00217","volume":"9","author":"GR Dos Passos","year":"2018","unstructured":"Dos Passos GR, Oliveira LM, da Costa BK et al (2018) MOG-IgG-associated optic neuritis, encephalitis, and myelitis: lessons learned from neuromyelitis optica spectrum disorder. Front Neurol 9:217","journal-title":"Front Neurol"},{"issue":"3","key":"1356_CR4","first-page":"205521731878782","volume":"4","author":"L Pandit","year":"2018","unstructured":"Pandit L, Mustafa S, Nakashima I, Takahashi T, Kaneko K (2018) MOG-IgG-associated disease has a stereotypical clinical course, asymptomatic visual impairment and good treatment response. Mult Scler J Exp Transl Clin 4(3):2055217318787829","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"1356_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","volume":"15","author":"M Reindl","year":"2019","unstructured":"Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89\u2013102","journal-title":"Nat Rev Neurol"},{"key":"1356_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"issue":"11","key":"1356_CR7","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444\u20131452","journal-title":"Neurology"},{"issue":"12","key":"1356_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","volume":"8","author":"AK Probstel","year":"2015","unstructured":"Probstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T (2015) Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype. J Neuroinflamm 8(12):46. https:\/\/doi.org\/10.1186\/s12974-015-0256-1","journal-title":"J Neuroinflamm"},{"issue":"1","key":"1356_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, H\u00fcmmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, Neuromyelitis Optica Study Group (NEMOS) (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflamm 13(1):280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0","journal-title":"J Neuroinflamm"},{"issue":"3","key":"1356_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","volume":"71","author":"J Kitley","year":"2014","unstructured":"Kitley J, Waters P, Woodhall M, Leite MI, Murchison A, George J et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276\u2013283","journal-title":"JAMA Neurol"},{"key":"1356_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.msard.2018.07.022","volume":"26","author":"B Konuskan","year":"2018","unstructured":"Konuskan B, Yildirim M, Gocmen R, Okur TD, Polat I, Kilic H et al (2018) Retrospective analysis of children with myelin oligodendrocyte glycoprotein antibody-related disorders. Mult Scler Relat Disord 26:1\u20137. https:\/\/doi.org\/10.1016\/j.msard.2018.07.022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"1356_CR12","doi-asserted-by":"publisher","first-page":"205521731667563","DOI":"10.1177\/2055217316675634","volume":"24","author":"L Pandit","year":"2016","unstructured":"Pandit L, Sato DK, Mustafa S, Takahashi T, D'Cunha A, Malli C, Sudhir A, Fujihara K (2016) Relapsing optic neuritis and isolated transverse myelitis are the predominant clinical phenotypes for patients with antibodies to myelin oligodendrocyte glycoprotein in India. Mult Scler J Exp Transl Clin 24(2):2055217316675634. https:\/\/doi.org\/10.1177\/2055217316675634","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"2","key":"1356_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/1352458515587751","volume":"22","author":"C Fernandez-Carbonell","year":"2016","unstructured":"Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T (2016) Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 22(2):174\u2013184. https:\/\/doi.org\/10.1177\/1352458515587751Epub 2015 Jun 3","journal-title":"Mult Scler."},{"key":"1356_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2019.00001","volume":"10","author":"L Mao","year":"2019","unstructured":"Mao L, Yang L, Kessi M, Fang H, Zhang C, Liwen W (2019) Myelin oligodendrocyte glycoprotein (MOG) antibody diseases in children in central South China clinical features, treatments, influencing factors, and outcomes. Frontiers Neurol 10:1\u201311","journal-title":"Frontiers Neurol"},{"issue":"12","key":"1356_CR15","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1093\/brain\/awx276","volume":"140","author":"M Jurynczyk","year":"2017","unstructured":"Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A et al (2017) Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 140(12):3128\u20133138. https:\/\/doi.org\/10.1093\/brain\/awx276[published correction appears in Brain. 2018 Apr 1;141(4):e31)]","journal-title":"Brain"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-020-01356-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-020-01356-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,7]],"date-time":"2021-08-07T10:59:07Z","timestamp":1628333947000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-020-01356-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,20]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1356"],"URL":"https:\/\/doi.org\/10.1007\/s13760-020-01356-9","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,20]]},"assertion":[{"value":"6 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author(s) declare(s) that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict interest"}},{"value":"We would like to state that our study was approved by appropriate Ethics Committee according to the International standards and we declare no authors did any intervention involving animals or humans here.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Written informed consent has been taken from the patients for participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}